No retraction, correction or concern found when last checked on Nov 5, 2026.

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

Nicholas C. Wu, Meng Yuan, Hejun Liu and 10 more

Cell Reports · 2020 · CC BY

doi:10.1016/j.celrep.2020.108274

Abstract

IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 because of structural constraints in binding the RBD (mode A). However, a small subset of IGHV3-53 antibodies to the RBD contain a longer CDR H3. Crystal structures of two IGHV3-53 neutralizing antibodies here demonstrate that a longer CDR H3 can be accommodated in a different binding mode (mode B). These two classes of IGHV3-53 antibodies both target the ACE2 receptor binding site, but with very different angles of approach and molecular interactions. Overall, these findings emphasize the versatility of IGHV3-53 in this common antibody response to SARS-CoV-2, where conserved IGHV3-53 germline-encoded features can be combined with very different CDR H3 lengths and light chains for SARS-CoV-2 RBD recognition and virus neutralization.

References 41

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
Features and development of Coot · 2010
No notice
10.
MolProbity : all-atom structure validation for macromolecular crystallography · 2009
No notice
11.
REFMAC 5 for the refinement of macromolecular crystal structures · 2011
No notice
12.
Phaser crystallographic software · 2007
No notice
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
PHENIX : a comprehensive Python-based system for macromolecular structure solution · 2010
No notice
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) · 2020
No notice
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 · 2020
No notice
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
No notice
29.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 · 2020
No notice
32.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020
No notice
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
Structural basis of a shared antibody response to SARS-CoV-2 · 2020
No notice
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation · 2020
No notice
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 12

Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding · 2023
No notice
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants · 2021
No notice
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
No notice
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study · 2021
No notice
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class · 2021
Not checked
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection · 2021
No notice
Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies · 2021
No notice
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines · 2021
No notice
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies · 2021
No notice
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein · 2021
No notice
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant · 2021
No notice
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity · 2020
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.